Molecular Profiling of Chronic Upper-Airway Disease

Abstract

Chronic upper-airway diseases (CUADs), encompassing chronic rhinosinusitis, allergic rhinitis, and related inflammatory conditions, exhibit significant heterogeneity in clinical presentation and therapeutic response. Recent advances in molecular profiling have transformed our understanding of CUADs by elucidating distinct endotypes, pathogenic pathways, and therapeutic targets. This article reviews current evidence on the molecular landscape of chronic upper-airway disease, emphasizing the clinical implications of molecular diagnostics, risk stratification, and precision medicine. Evidence from recent PubMed-indexed studies and consensus guidelines is integrated to provide a comprehensive, practice-oriented resource for healthcare professionals.

Introduction

Chronic upper-airway diseases represent a substantial healthcare burden, affecting quality of life and predisposing to lower respiratory tract involvement. Traditionally classified based on clinical presentation and histopathology, these diseases are now increasingly understood through the lens of molecular endotyping. Molecular profiling—encompassing genomics, transcriptomics, proteomics, and metabolomics—provides insights into disease mechanisms, heterogeneity, and individualized therapy. In this review, we synthesize evidence on the molecular basis of CUADs, the impact of molecular diagnostics on clinical practice, and the relevance of personalized therapeutic strategies.

Epidemiology / Disease Burden

CUADs, particularly chronic rhinosinusitis (CRS) and allergic rhinitis (AR), affect an estimated 10-15% of the global population. CRS alone accounts for millions of outpatient visits annually, with significant direct and indirect healthcare costs. The prevalence varies geographically, influenced by environmental exposures, genetic predisposition, and diagnostic criteria. The disease burden is compounded by frequent comorbidities, including asthma, sleep disturbances, and recurrent infections, leading to impaired work productivity and reduced quality of life.

Pathophysiology

Molecular profiling has elucidated several pathogenic pathways in CUADs. CRS, for instance, is now stratified into endotypes based on cytokine signatures: type 2 (Th2-mediated, eosinophil-predominant) and non-type 2 (Th1/Th17-mediated, neutrophil-predominant) inflammation. Gene expression studies reveal upregulation of IL-4, IL-5, and IL-13 in Th2-dominant disease, while IFN-γ and IL-17A are prominent in non-type 2 phenotypes. Epigenetic modifications, altered barrier function genes (e.g., filaggrin, tight junction proteins), and dysbiosis of the sinonasal microbiome further contribute to pathogenesis. These molecular insights have direct implications for targeted therapies.

Risk Factors

Risk factors for CUADs include genetic predisposition (e.g., polymorphisms in IL-33, TSLP, and HLA loci), environmental exposures (allergens, pollutants, tobacco smoke), and host factors such as immune dysregulation and epithelial barrier dysfunction. Recent molecular studies have identified single nucleotide polymorphisms associated with higher disease susceptibility and severe phenotypes. Occupational exposures and urbanization increase risk, while early-life viral infections may prime the airway immune response toward chronic inflammation.

Clinical Features

CUADs present with persistent nasal congestion, rhinorrhea, facial pain or pressure, hyposmia, and postnasal drip. Polypoid disease, more common in Th2-skewed endotypes, is associated with severe symptoms and frequent exacerbations. Molecular subtyping correlates with clinical features: type 2 inflammation often predicts corticosteroid responsiveness and comorbid asthma, while non-type 2 disease shows limited response and higher risk of recurrence. Emerging evidence highlights the utility of biomarker-driven symptom assessment for accurate endotyping and prognosis.

Diagnosis

Diagnosis of CUADs relies on clinical criteria, endoscopic evaluation, and imaging. Molecular profiling, using nasal brushings, tissue biopsies, or nasal secretions, now complements traditional diagnostics. Biomarkers such as periostin, eosinophil cationic protein, and cytokine signatures (e.g., IL-5, IL-13) facilitate endotype classification. Genetic assays and exhaled nitric oxide are under investigation for routine clinical use. Integration of molecular data improves diagnostic accuracy and guides personalized therapy selection.

Treatment & Management

Management strategies for CUADs are tailored to disease severity, endotype, and comorbidities. Standard therapies include intranasal corticosteroids, saline irrigation, antihistamines, and surgical interventions. Molecular profiling enables targeted therapy: biologics such as anti-IL-5 (mepolizumab), anti-IL-4/13 (dupilumab), and anti-IgE (omalizumab) are effective in Th2-high endotypes. Non-type 2 disease may require alternative approaches, including macrolide antibiotics and immunomodulators. Regular assessment of molecular biomarkers informs treatment response and risk of relapse.

Recent Advances / Emerging Therapies

Recent advances include high-throughput sequencing, transcriptomic analysis, and single-cell profiling to delineate novel disease subsets. New therapeutics targeting epithelial alarmins (TSLP, IL-33), Janus kinase inhibitors, and microbiome modulation are in clinical trials. Personalized medicine platforms integrating molecular, clinical, and imaging data are being developed for real-time decision support. The identification of predictive biomarkers for biologic response is a major focus of ongoing research, aiming to optimize outcomes and minimize overtreatment.

Guideline Recommendations

Contemporary guidelines, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) and the American Academy of Otolaryngology, advocate for a stepwise approach to CUAD management. Molecular endotyping is increasingly recommended for refractory cases and biologic therapy selection. Guidelines emphasize multidisciplinary care, regular monitoring of disease activity, and shared decision-making based on molecular and clinical parameters. Implementation of molecular diagnostics in routine practice is evolving, with calls for standardized protocols and cost-effectiveness studies.

Conclusion

Molecular profiling has revolutionized the management of chronic upper-airway diseases by uncovering mechanistic heterogeneity, enabling precise endotyping, and guiding targeted therapies. Integration of molecular diagnostics into clinical practice enhances diagnostic accuracy, informs prognosis, and optimizes individualized management. Ongoing research into novel biomarkers and emerging therapeutics promises to further refine the precision medicine paradigm, ultimately improving patient outcomes in this diverse and burdensome group of diseases.